CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Income Statement [Abstract]
Net sales	$ 1,412.7	$ 1,329.9
Cost of sales	301.6	286.9
Gross profit	1,111.1	1,043.0
Selling, general, and administrative expenses	465.7	428.4
Research and development expenses	254.6	256.7
Certain litigation expenses	10.9	8.9
Separation costs (Note 3)	4.2	0.0
Other operating income	(19.1)	0.0
Operating income, net	394.8	349.0
Interest income, net	(36.5)	(16.5)
Other non-operating income, net	(2.6)	(5.7)
Income from continuing operations before provision for income taxes	433.9	371.2
Provision for income taxes	70.3	46.3
Net income from continuing operations	363.6	324.9
(Loss) income from discontinued operations, net of tax	(7.2)	26.1
Net income	356.4	351.0
Net loss attributable to noncontrolling interest	(1.6)	(0.9)
Net income attributable to Edwards Lifesciences Corporation	$ 358.0	$ 351.9
Basic:
Continuing operations (in dollars per share)	$ 0.62	$ 0.54
Discontinued operations (in dollars per share)	(0.01)	0.04
Basic earnings per share (in dollars per share)	0.61	0.58
Diluted:
Continuing operations (in dollars per share)	0.62	0.54
Discontinued operations (in dollars per share)	(0.01)	0.04
Diluted earnings per share (in dollars per share)	$ 0.61	$ 0.58
Weighted-average number of common shares outstanding:
Basic (in shares)	586.9	601.6
Diluted (in shares)	587.8	604.1